Below are the financial statements of IPCA Laboratories, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of INR | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue from operations | 89,395.9a | 77,050.4b | 62,443.2b |
| Other income | 928a | 1,247.7b | 1,256.2b |
| Total income | 90,323.9a | 78,298.1b | 63,699.4b |
| Expenses | — | — | — |
| Cost of materials consumed | -22,768.2a | -22,163.2b | -17,086.5b |
| Purchases of stock-in-trade | - | -4,900.7b | -4,971.9b |
| Changes in inventories of finished goods, work-in-progress and stock-in-trade | - | -1,306.4b | -1,006.7b |
| Employee benefits expense | - | -17,084.3b | -12,876.4b |
| Finance costs | - | -1,382.7b | -455.4b |
| Depreciation and amortisation expense | - | -3,572.4b | -2,615.6b |
| Other expenses | - | -20,997b | -17,234b |
| Total expenses | - | -68,793.9b | -56,246.5b |
| Profit from ordinary activity before share of profit/(loss) of associates & joint venture, exceptional items & tax | - | 9,504.2b | 7,452.9b |
| Exceptional items: (Income)/expenses | - | 1,077.5b | - |
| Profit before tax | - | 8,426.7b | 7,452.9b |
| Tax expense | — | — | — |
| Current tax | - | -3,132.4b | -2,301.4b |
| Short/(excess) provision of earlier years | - | -30.6b | 2.2b |
| Deferred tax liability/(asset) | - | -32.8b | -230b |
| Profit for the period from continuing operations before share of profit/(loss) of associates & joint venture | - | 5,292.1b | 4,919.3b |
| Add share of profit/(less loss) of associates & joint venture (net of tax) accounted by using the equity method | - | -62.9b | -129.4b |
| Profit for the period from continuing operations before non-controlling interest | - | 5,229.2b | 4,789.9b |
| Less profit/(add loss) attributable to non-controlling interest | - | -244.3b | 76.7b |
| Profit for the period attributable to owners of the company | - | 5,473.5b | 4,713.2b |
| Revenue from operations | - | 77,050.4a | - |
| Other income | - | 1,247.7a | - |
| Total income | - | 78,298.1a | - |
| Cost of materials consumed | - | -22,163.2a | - |
| Purchase of stock-in-trade | -5,477.8a | -4,900.7a | - |
| Changes in inventories of finished goods, work-in-progress and stock-in-trade | -460.5a | -1,306.4a | - |
| Employee benefit expense | -19,839.9a | -17,084.3a | - |
| Finance cost | -849.3a | -1,382.7a | - |
| Depreciation & amortisation expense | -3,978.2a | -3,572.4a | - |
| Other expenses | -24,509.1a | -20,997a | - |
| Total expenses | -76,962a | -68,793.9a | - |
| Profit from ordinary activity before share of profit/(loss) of associates & joint venture, exceptional items & tax | 13,361.9a | 9,504.2a | - |
| Exceptional items: (income)/expenses | 2,050.5a | 1,077.5a | - |
| Profit after exceptional item & before tax | 11,311.4a | 8,426.7a | - |
| Current tax | -3,731.4a | -3,132.4a | - |
| Short/(excess) provision of earlier years | -10.9a | -30.6a | - |
| Deferred tax liability/(asset) | -284.4a | -32.8a | - |
| Profit for the period from continuing operations before share of profit/(loss) of associates & joint venture | 7,875.3a | 5,292.1a | - |
| Share of profit/(loss) of associates & joint venture (net of tax) accounted by using the equity method | -22.9a | -62.9a | - |
| Profit for the period from continuing operations before non - controlling interest | 7,852.4a | 5,229.2a | - |
| Less/(add): Share of non-controlling interest - profit/(loss) | 475.6a | -244.3a | - |
| Profit for the period attributable to owners of the company | 7,376.8a | 5,473.5a | - |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore IPCA Laboratories’s data sources below and access millions more through our Disclosure Search.